Mumbai-based drug major Lupin Limited on 2 February 2015 announced that it had received final approval from US Food and Drugs Administration (USFDA) for its vancomycin hydrochloride capsules used for treating diarrhea.
The approval was given for the marketing of 125 mg and 250 mg strength of capsules in the US market. Lupin Pharmaceuticals Inc, Lupin’s US subsidiary, would market the generic version of Vancocin capsules of ANI Pharmaceuticals Inc.
Vancomycin is an antibiotic useful for the treatment of a number of bacterial infections. Lupin's vancomycin capsules are indicated for the treatment of C. difficile-associated diarrhoea and also for the treatment of enterocolitis caused by staphylococcus aureus (including methicillin-resistant strains).
Where: in US
When: 2 February 2015